Back

Accesses to anti-amyloid disease-modifying therapy impact awareness about cardiac amyloidosis and clinical practice: insights from an international survey

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - treatment 9 Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor David Niederseer

Hochgebirgsklinik Davos, Davos Wolfgang (Switzerland)

7 More presentations in this session

Presentation thumbnail
Real world data using sacubitril/valsartan in CKD stage 4 and 5 is associated with improved ejection fraction and may have renoprotective effects.
Doctor M. Sweeney (London, GB)
Abstract Slides Video
Presentation thumbnail
Real-life management of heart failure: evaluation of medication optimisation in different phenotypes.
Miss H. Hauksdottir (Reykjavik, IS)
Abstract Slides Video
Presentation thumbnail
The effect of an incentive billing code on heart failure management in primary care: a population-based study
Doctor S. Zhou (Toronto, CA)
Abstract Slides Video
Presentation thumbnail
A novel dual-action insulin secreting and natriuretic peptide, CRRL 101, a potential therapy for diabetic cardiomyopathy
Doctor I. Isaia (Rochester, US)
Abstract Slides Video
Presentation thumbnail
Evaluation of the effects of the Sodium-glucose cotransporter 2 inhibitors and sacubitril/valsartan combined therapy in patients with HFrEF: echocardiographic study.
Doctor I. Fumarulo (Rome, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic heart failure - treatment 9

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Cardiac amyloidosis awareness among physicians around the world: insights from an international survey
thumbnail
Congress Presentation
Cardiac amyloidosis awareness comparison between HF-cardiologists, non-HF-cardiologists and other specialties around the world: insights from international survey
thumbnail
Congress Presentation
Understanding the patient burden in transthyretin cardiac amyloidosis is significantly improved with continuing medical education

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources